From Financial Modeling Prep: 2025-04-30 13:00:00

In anticipation of Moderna Inc.’s quarterly earnings report, analysts predict an EPS of -$2.92, showing a 4.9% improvement from last year. However, revenue is expected to decline by 24% to $115.3 million due to reduced demand for the COVID-19 vaccine.

The revenue decline is mainly attributed to decreased demand for Moderna’s COVID-19 vaccine, with projected sales of $112 million. The company’s RSV vaccine, mResvia, is expected to contribute minimally with $10 million in sales.

Moderna’s financial metrics present challenges with a negative P/E ratio of -3.02, but it maintains a strong current ratio of 3.67. Investors will be looking for updates on the company’s pipeline during the earnings report.

Analysts have slightly adjusted the consensus EPS estimate downward by 0.1%, raising concerns about potential earnings misses. The Zacks Consensus Estimate predicts a quarterly loss of $2.91 per share, indicating uncertainty in Moderna’s performance.

Despite financial challenges, Moderna’s low debt-to-equity ratio of 0.065 and strong current ratio of 3.67 provide some stability. Investors will be closely monitoring the earnings call for insights into immediate price changes and future earnings expectations.



Read more at Financial Modeling Prep:: Moderna Inc. (NASDAQ: MRNA) Quarterly Earnings Pre…